Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11.

Article  PubMed  PubMed Central  Google Scholar 

Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13.

Article  PubMed  Google Scholar 

Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38:789–95.

Article  CAS  PubMed  Google Scholar 

Shah R, Gayat E, Januzzi JL Jr, Sato N, Cohen-Solal A, diSomma S, et al. Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. J Am Coll Cardiol. 2014;63:778–85.

Article  PubMed  Google Scholar 

Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis. 2018;61:151–6.

Article  PubMed  Google Scholar 

WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.

Seko Y, Kato T, Morimoto T, Yaku H, Inuzuka Y, Tamaki Y, et al. Association between body mass index and prognosis of patients hospitalized with heart failure. Sci Rep. 2020;10:16663.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jones NR, Ordóñez-Mena JM, Roalfe AK, Taylor KS, Goyder CR, Hobbs FR, et al. Body mass index and survival in people with heart failure. Heart. 2023;109:1542–9.

Article  PubMed  Google Scholar 

Ruan GT, Deng L, Xie HL, Shi JY, Liu XY, Zheng X, et al. Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia. Cancer Metab. 2024;12:3.

Article  PubMed  PubMed Central  Google Scholar 

Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest. 2003;123:1460–6.

Article  PubMed  Google Scholar 

Mohamad Alahmad MA, Acharya P, Gibson CA, Wiley M, Hockstad E, Gupta K. Cachexia is associated with adverse outcomes in patients admitted with heart failure. Am J Cardiol. 2023;186:30–5.

Article  PubMed  Google Scholar 

Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clinical Nutrition. 2008;27:793–9.

Article  CAS  PubMed  Google Scholar 

Franssen C, Chen S, Hamdani N, Paulus WJ. From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. Heart. 2016;102:320–30.

Article  CAS  PubMed  Google Scholar 

Shiraishi Y, Kohsaka S, Abe T, Mizuno A, Goda A, Izumi Y, et al. Validation of the get with the guideline-heart failure risk score in Japanese patients and the potential improvement of its discrimination ability by the inclusion of B-type natriuretic peptide level. Am Heart J. 2016;171:33–9.

Article  PubMed  Google Scholar 

Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107–15.

Article  CAS  PubMed  Google Scholar 

The Examination Committee of Criteria for ‘Obesity Disease’ in Japan, Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–92.

Article  Google Scholar 

Ota T, Takamura T, Hirai N, Kobayashi K. Preobesity in World Health Organization classification involves the metabolic syndrome in Japanese. Diabetes Care. 2002;25:1252–3.

Article  PubMed  Google Scholar 

Hickson M. Malnutrition and ageing. Postgrad Med J. 2006;82:2–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Higuchi S, Kohno T, Kohsaka S, Shiraishi Y, Takei M, Goda A, et al. Different impact of beta-blockers on long-term mortality in heart failure patients with and without chronic obstructive pulmonary disease. J Clin Med. 2021;10:4378.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sato Y, Yoshihisa A, Kimishima Y, Yokokawa T, Abe S, Shimizu T, et al. Prognostic factors in heart failure patients with cardiac cachexia. J Geriatr Cardiol. 2020;17:26–34.

CAS  PubMed  PubMed Central  Google Scholar 

Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015;66:403–69.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

Article  CAS  PubMed  Google Scholar 

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390:2627–42.

Higuchi S, Matsumoto H, Masaki R, Hirano T, Fuse S, Tanisawa H, et al. Potential confounders of the obesity paradox in older patients following transcatheter aortic valve replacement. Eur Geriatr Med. 2024;15:179–87.

Article  PubMed  Google Scholar 

Nogueira-Ferreira R, Sousa-Nunes F, Leite-Moreira A, Moreira-Costa L, Vitorino R, Lara Santos L, et al. Cancer- and cardiac-induced cachexia: same fate through different inflammatory mediators? Inflamm Res. 2022;71:771–83.

Article  CAS  PubMed  Google Scholar 

Ye LF, Li XL, Wang SM, Wang YF, Zheng YR, Wang LH. Body mass index: an effective predictor of ejection fraction improvement in heart failure. Front Cardiovasc Med. 2021;8:586240.

Article  PubMed  PubMed Central  Google Scholar 

Coats AJS, Butler J, Tsutsui H, Doehner W, Filippatos G, Ferreira JP, et al. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved. J Cachexia Sarcopenia Muscle. 2024;15:412–24.

Article  PubMed  Google Scholar 

Adamson C, Jhund PS, Docherty KF, Bělohlávek J, Chiang CE, Diez M, et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail. 2021;23:1662–72.

Article  CAS  PubMed  Google Scholar 

Aldafas R, Crabtree T, Alkharaiji M, Vinogradova Y, Idris I. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age Ageing. 2024;53:afad254.

Article  PubMed  PubMed Central  Google Scholar 

Wang X, Wu N, Sun C, Jin D, Lu H. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023;15:113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruppert Z, Neuperger P, Rákóczi B, Gémes N, Dukay B, Hajdu P, et al. Characterization of obesity-related diseases and inflammation using single cell immunophenotyping in two different diet-induced obesity models. Int J Obes. 2024;48:1568–76.

Article  CAS  Google Scholar 

Jahangiri S, Malek M, Kalra S, Khamseh ME. The effects of sodium-glucose cotransporter 2 inhibitors on body composition in type 2 diabetes mellitus: a narrative review. Diabetes Ther. 2023;14:2015–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–84.

Article  CAS  PubMed  Google Scholar 

Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and Type 2 Diabetes. N Engl J Med. 2024;390:1394–407.

Article  CAS  PubMed